Intravenous iron isomaltoside 1000 (Monofer®) reduces postoperative anaemia in preoperatively non-anaemic patients undergoing elective or subacute coronary artery bypass graft, valve replacement or a combination thereof: a randomized double-blind placebo-controlled clinical trial (the PROTECT trial)

相似書籍

• Introducing iron isomaltoside 1000 (Monofer®)—development rationale and clinical experience
  由: Kalra, Philip A.
  出版: (2011)
• A randomized, open-label trial of iron isomaltoside 1000 (Monofer®) compared with iron sucrose (Venofer®) as maintenance therapy in haemodialysis patients
  由: Bhandari, Sunil, et al.
  出版: (2015)
• Efficacy and safety of iron isomaltoside (Monofer(®)) in the management of patients with iron deficiency anemia
  由: Kalra, Philip A, et al.
  出版: (2016)
• A Randomized, Open-Label, Non-Inferiority Study of Intravenous Iron Isomaltoside 1,000 (Monofer) Compared With Oral Iron for Treatment of Anemia in IBD (PROCEED)
  由: Reinisch, Walter, et al.
  出版: (2013)
• The effect of perioperative intravenously administered iron isomaltoside 1000 (Monofer®) on transfusion requirements for patients undergoing complex valvular heart surgery: study protocol for a randomized controlled trial
  由: Lee, Seung Hyun, et al.
  出版: (2018)